anlotinib hydrochloride + sintilimab + gemcitabine + cisplatin

This combination therapy, often referred to as the SAGC regimen, is a multi-modality treatment being evaluated for advanced biliary tract cancer. It consists of **anlotinib hydrochloride**, an oral small-molecule multi-target tyrosine kinase inhibitor that inhibits VEGFR1/2/3, FGFR1-4, PDGFRα/β, and c-Kit; **sintilimab**, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor to enhance anti-tumor immune responses; and the standard chemotherapy doublet of **gemcitabine** and **cisplatin**. The regimen aims to provide synergistic effects by combining anti-angiogenesis, immune checkpoint inhibition, and cytotoxic chemotherapy. A Phase II trial (NCT04300959) led by Zhejiang Cancer Hospital demonstrated that this four-drug combination significantly improved progression-free survival and objective response rates compared to gemcitabine and cisplatin alone as a first-line treatment for unresectable or metastatic biliary tract cancer.

Other names

Anlotinib + Sintilimab + GemCisAnlotinib + PD-1 + Gemcitabine + CisplatinAnlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus Cisplatin